Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

First Rapid COVID-19 Antigen Test Gets Green Light

Executive Summary

In a potential game-changer in the ongoing fight to expand COVID-19 testing, the FDA has authorized a new kind of test that can be used by certain health care providers on-site to diagnose patients with the SARS-CoV-2 virus within minutes instead of days.

You may also be interested in...



COVID-19: How Rapid Diagnostic Development Helped South Korea ‘Flatten The Curve’

A new US FDA report found that South Korea's diagnostic development strategy, as well as contract tracing, helped the country limit the spread of COVID-19.

Abbott Mass Distributes Rapid COVID-19 Tests, Offers App So Consumers Can Display Test Results

BinaxNOW rapid tests, the size of a credit card with no other equipment required, are sold directly to organizations at $5 each and an at-home version, with use guided through digital links, is available at $25 per test. It can be paired with NAVICA app, allowing consumers to display negative results through a temporary digital health certificate.

First COVID-19 At-Home Test That Doesn’t Require A Prescription Authorized By The FDA

Ellume Health’s COVID-19 Home Test isn’t just a relatively fast, accurate and easy-to-administer antigen diagnostic, but it’s also available over-the-counter, which greatly expands public access to such tests.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT126728

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel